Seaport Therapeutics Prices Initial Public Offering at $18.00 Per Share, Raising $254.88 Million for Clinical Development

summarizeSummary

Seaport Therapeutics, a clinical-stage company, has finalized its initial public offering, selling 14.16 million shares at $18.00 each to raise $254.88 million in gross proceeds, providing substantial capital to advance its neuropsychiatric drug pipeline.

check_boxKey Events

• Initial Public Offering Priced

  Seaport Therapeutics priced its IPO at $18.00 per share, offering 14,160,000 shares of common stock.

• Significant Capital Raised

  The offering is expected to generate approximately $254.88 million in gross proceeds and $233.9 million in net proceeds for the company.

• Funding for Clinical Pipeline

  Proceeds will primarily fund the advancement of GlyphAllo (SPT-300) into Phase 3 and GlyphAgo (SPT-320) through Phase 2a and Phase 2b clinical trials, extending the company's cash runway into 2029.

• Nasdaq Listing

  The common stock has been approved for listing on the Nasdaq Global Select Market under the symbol "SPTX."

auto_awesomeAnalysis

This 424B4 filing finalizes the terms and pricing of Seaport Therapeutics' initial public offering, which was previously announced. The company is raising approximately $233.9 million in net proceeds by selling 14.16 million shares at $18.00 per share. This significant capital infusion is earmarked to fund the development of its lead product candidates, GlyphAllo (SPT-300) and GlyphAgo (SPT-320), through Phase 2b and into Phase 3 clinical development, as well as other preclinical programs. The proceeds are expected to provide a cash runway into 2029, which is a critical milestone for a clinical-stage biotechnology company. While the offering introduces immediate dilution for new investors, the successful completion of the IPO at a price of $18.00 per share (compared to today's market price of $19.78) demonstrates investor confidence and significantly de-risks the company's near-term funding needs for its ambitious R&D pipeline.